Spark Therapeutics Inc (NASDAQ:ONCE) was the recipient of a large increase in short interest in December. As of December 29th, there was short interest totalling 4,833,489 shares, an increase of 30.0% from the December 15th total of 3,717,704 shares. Based on an average daily trading volume, of 1,258,947 shares, the short-interest ratio is currently 3.8 days. Approximately 15.1% of the shares of the company are sold short.
Spark Therapeutics (NASDAQ ONCE) opened at $50.55 on Friday. Spark Therapeutics has a fifty-two week low of $41.06 and a fifty-two week high of $91.75. The company has a market capitalization of $1,906.89, a P/E ratio of -7.00 and a beta of 3.14.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. During the same period in the previous year, the company earned ($1.07) EPS. Spark Therapeutics’s revenue was up 45.8% compared to the same quarter last year. research analysts anticipate that Spark Therapeutics will post -7.55 earnings per share for the current fiscal year.
In other news, CEO Jeffrey D. Marrazzo sold 20,000 shares of Spark Therapeutics stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $71.54, for a total value of $1,430,800.00. Following the completion of the transaction, the chief executive officer now owns 250,000 shares in the company, valued at approximately $17,885,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $83.30, for a total value of $416,500.00. Following the completion of the transaction, the insider now owns 215,000 shares of the company’s stock, valued at approximately $17,909,500. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,309 shares of company stock worth $4,141,385. Insiders own 7.30% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. Cornerstone Capital Management Holdings LLC. increased its holdings in shares of Spark Therapeutics by 3.2% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock valued at $662,000 after purchasing an additional 342 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 389 shares during the last quarter. California Public Employees Retirement System increased its stake in Spark Therapeutics by 2.1% during the second quarter. California Public Employees Retirement System now owns 39,100 shares of the biotechnology company’s stock worth $2,336,000 after acquiring an additional 800 shares during the last quarter. Great West Life Assurance Co. Can increased its stake in Spark Therapeutics by 47.3% during the third quarter. Great West Life Assurance Co. Can now owns 3,939 shares of the biotechnology company’s stock worth $351,000 after acquiring an additional 1,264 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in Spark Therapeutics by 16.8% during the second quarter. Legal & General Group Plc now owns 8,931 shares of the biotechnology company’s stock worth $532,000 after acquiring an additional 1,286 shares during the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have weighed in on ONCE shares. Goldman Sachs Group reiterated a “buy” rating and issued a $111.00 target price on shares of Spark Therapeutics in a report on Friday, October 6th. BMO Capital Markets set a $89.00 price target on Spark Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 10th. Cowen reissued a “buy” rating and issued a $95.00 price target on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Barclays boosted their price target on Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a research report on Friday, October 13th. Finally, Cantor Fitzgerald reduced their target price on Spark Therapeutics from $105.00 to $94.00 and set a “buy” rating on the stock in a research report on Friday, October 13th. Three analysts have rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $74.45.
ILLEGAL ACTIVITY WARNING: This story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://ledgergazette.com/2018/01/19/spark-therapeutics-inc-once-short-interest-update.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.